PMID: 3752072Sep 1, 1986Paper

Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
M Lam, D J Adelstein

Abstract

Cisplatin (cis-diamminedichloroplatinum II), a chemotherapeutic agent used against epithelial neoplasms, is known to cause hypomagnesemia and renal magnesium wasting. In order to further characterize the effect of multiple doses of this drug upon serum magnesium levels and renal magnesium handling, we prospectively studied 28 patients who received a total of 82 doses of cisplatin. All patients developed hypomagnesemia that was dose-related (r = .66, P less than .001, n = 101); the lowest serum magnesium level reached in individual patients ranged from 0.3 to 1.7 mg/dL. Renal magnesium wasting was documented in 19 patients, with urinary fractional excretion of magnesium ranging from 2.9% to 22.3% despite serum magnesium levels of greater than or equal to 1.5 mg/dL. Evidence of renal tubular injury (renal tubular epithelial cells or tubular cell casts) was detected in 47 of 47 urine sediment examinations performed two to four days after cisplatin administration. There was no clear evidence that cisplatin caused defects in renal handling of electrolytes other than magnesium; in fact, 16 of the 28 patients demonstrated avid renal reabsorption of one or more other electrolytes despite significant magnesium wasting. We conclude that ...Continue Reading

References

Jun 1, 1979·Annals of Internal Medicine·R L Schilsky, T Anderson
Sep 1, 1979·Annals of Internal Medicine·C F WinklerH DeBandi
Nov 1, 1981·Annals of Internal Medicine·J D Blachley, J B Hill

❮ Previous
Next ❯

Citations

Apr 29, 1998·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·R K Rude
Jan 28, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Rodney J HunterJudith A Smith
Jun 15, 2005·Journal of Pharmacological and Toxicological Methods·Susan G Emeigh Hart
Feb 1, 1989·Chest·B ChernowA L Warshaw
Sep 1, 1999·Kidney International·K J KellyJ V Bonventre
Oct 24, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roderick SkinnerAndrew D J Pearson
Mar 5, 2016·European Journal of Pharmacology·George LiamisMoses S Elisaf
Nov 15, 2006·Clinical Oncology : a Journal of the Royal College of Radiologists·E HodgkinsonR E Coleman
Aug 30, 2001·Critical Care Clinics·M Kapoor, G Z Chan
Apr 14, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Sheron LatchaCarlos D Flombaum
Apr 23, 1999·Cancer Treatment Reviews·H Lajer, G Daugaard
Mar 5, 2013·PloS One·Kristien J LedeganckBenedicte Y De Winter
Feb 8, 2014·Japanese Journal of Clinical Oncology·Tatsuya YoshidaYuichiro Ohe
Nov 9, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Annelies A van AngelenRené J M Bindels
Apr 7, 2017·Journal of Nephrology·Sandhya Manohar, Nelson Leung
Apr 24, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Roderick Skinner
Aug 27, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jacob Atsmon, Eran Dolev
Jan 1, 1997·Medical and Pediatric Oncology·G AricetaA Navajas
Nov 10, 2011·Toxins·Ronald P MillerWilliam Brian Reeves
Jul 1, 2009·Nature Reviews. Nephrology·Vaibhav SahniZiauddin Ahmed
Aug 20, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Chris D BartonDaniel B Hawcutt
Dec 25, 2004·Cancer Chemotherapy and Pharmacology·H LajerG Daugaard
Mar 22, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·G T SandersR Sanders
Oct 17, 2017·Journal of the Chinese Medical Association : JCMA·Tse-Chou ChengChia-Fang Tsai
May 7, 1998·Endocrine Reviews·S C YeungR F Gagel
Oct 30, 2015·American Journal of Physiology. Renal Physiology·Andrea M P Romani
Aug 18, 2017·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Maria Q B Petzel, Leah Hoffman
Dec 1, 1993·The Annals of Pharmacotherapy·A J Anand, B Bashey
Jun 12, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Thana PatimarattanananNuttapong Ngamphaiboon
Nov 29, 2011·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Eiji Kusano
Jun 22, 2018·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Maria Q B Petzel, Leah Hoffman
Apr 29, 2021·The Proceedings of the Nutrition Society·Willem BosmanJeroen H F de Baaij

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

© 2021 Meta ULC. All rights reserved